Prelude Therapeutics Secures $60 Million and Expands Management Team to Develop Drugs Targeting Novel Molecular Mechanisms in Cancer

Prelude Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs that target key drivers of cancer cell growth, survival and resistance, secured $60 million in Series B financing; taking its total investments to date to $95 million. The financing was co-led by Prelude’s two existing institutional investors, including OrbiMed Advisors LLC.

Click here to see full DE Bio article.